# Diasome Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/diasome-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cleveland, US
- Website: www.diasome.com
- Latest round: Series B (Apr 15, 2008)
- Investors on record: 2

## About

Diasome Pharmaceuticals, Inc. is a US-based biotechnology firm specializing in innovative therapeutic solutions for metabolic disorders, focusing on advanced delivery systems to enhance patient care.Founded in 2004 and headquartered in Cleveland, US, Diasome Pharmaceuticals, Inc. develops therapeutic technologies for metabolic health. The company was established by Robert Geho and has engaged in multiple funding rounds, including a Series C round in June 2023, raising USD 9.000 mn, bringing the total amount raised to USD 9.000 mn and a current valuation of USD 119.156 mn.Diasome Pharmaceuticals, Inc. provides innovative therapeutic solutions targeting metabolic disorders, particularly through its HDV technology. This technology aims to restore hepatocyte metabolism, addressing deficiencies related to conditions such as Type 1 Diabetes and Dyslipidemia. The HDV system supports both injectable and oral administration methods to meet diverse patient needs, leveraging drug payload advancements to optimize therapeutic outcomes for healthcare providers and patients with metabolic diseases.The revenue model of Diasome Pharmaceuticals, Inc. is built on partnerships and direct-to-consumer sales for its HDV technology. Collaborations with healthcare providers facilitate product distribution to patients managing metabolic conditions, with revenue stemming from structured agreements that may involve bulk purchasing by medical facilities or direct supply to pharmacies, ensuring competitive pricing aligned with market demands.With the recent Series C funding round completed in June 2023, in which Diasome Pharmaceuticals, Inc. raised USD 9.000 mn, the company plans to focus on expanding its product offerings and entering new geographic markets. In February 2024, they intend to launch upcoming products utilizing the latest technology advancements. The funding will be directed towards broadening their reach in regions significantly impacted by metabolic disorders, enhancing distribution channels, and supporting ongoing research in metabolic treatment solutions.

## Funding rounds

- Series B, Apr 15, 2008 — Quaker Partners Management, Devon Park Bioventures

## Investors

- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series B
- Devon Park Bioventures (https://capitalatlas.ai/funds/devon-park-bioventures) — Series B